Serum GP73, a Marker for Evaluating Progression in Patients with Chronic HBV Infections

Wei, Hongshan; Li, Boan; Zhang, Renwen; Hao, Xiaohua; Huang, Yongxiong; Qiao, Yong; Hou, Jun; Li, Xin; Li, Xingwang

doi:10.1371/journal.pone.0053862

Cited by 37 publications

(38 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This raises the potential for serum GP73 to be a noninvasive marker for hepatic necroinflammation and liver fibrosis. Subsequently, several researchers demonstrated that serum GP73 levels were significantly correlated with the staging of fibrosis and that these levels were proposed as markers for the diagnosis of both significant liver fibrosis and cirrhosis in patients with chronic HBV infections. However, they did not look into the relationship of pathological grading or staging with elevated serum GP73 levels.…”

Section: Discussionmentioning

confidence: 99%

Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection

Shen

Pan

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

As a noninvasive marker, serum alanine aminotransferase (ALT) has limitations, because a large proportion of patients chronically infected with hepatitis B virus (HBV) suffer from severe hepatic necroinflammation, but have normal or mildly elevated ALT. In the present study, we aimed to investigate the potential value of serum Golgi protein 73 (GP73) in predicting significant hepatic necroinflamation among chronic HBV infected patients. A cohort of 497 chronic HBV infected patients was retrospectively recruited. Liver biopsy was performed in all patients and serum GP73 levels were measured by enzyme-linked immunosorbent assay. Serum GP73 increased in parallel with the increase in hepatic necroinflammatory activity grade (r = 0.682) and the stage of liver fibrosis (r = 0.539). The positive correlation of serum GP73 with the degree of hepatic necroinflammatory activity was statistically significant, while serum GP73 with the stage of liver fibrosis was weaker than that with hepatic necroinflammation. Furthermore, serum GP73 levels were significantly greater in patients with normal or mildly elevated ALT and significant hepatic necroinflammation (≥G2) than in patients with minimal to mild hepatic necroinflammation. The sensitivity and specificity of GP73 for the diagnosis of G2 hepatic necroinflammation was 42.35% and 95.0%, respectively, at a cut-off value of 88.38 ng/mL. When the cut-off value was set at 124.76 ng/mL, the sensitivity and specificity of GP73 for the diagnosis of G3 hepatic necroinflammation was 55.56% and 97.29%, respectively. These findings indicate that GP73 holds promise as an important candidate for diagnosing significant hepatic necroinflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection

Shen

Pan

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Consistent with our findings, Qiao et al . had also noticed that the increased serum GP73 in CHB patients with cirrhosis [24], and GP73 positive cells in the liver were gradually increased with the severity of liver fibrosis [25]. Therefore, serum GP73 could be considered a potential marker for cirrhosis.…”

Section: Discussionmentioning

confidence: 99%

Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

Golgi protein 73 (GP73) has been suggested as a serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, this has been challenged in recent years. In the present study, we found that the serum GP73 increased in HCC patients with cirrhosis but not in those without cirrhosis. The receiver operating characteristic curve (ROC) analysis demonstrated that serum GP73 had poor performance for differentiating HCC patients from cirrhosis patients. In addition, the immunohistochemistry revealed that aberrant expression of GP73 was primarily observed in cirrhotic and tumor liver tissues from both cirrhosis and HCC patients, but rarely in non-cirrhotic liver tissues from HCC patients without cirrhosis. Moreover, serum Alpha-fetoprotein in HCC patients with cirrhosis decreased sharply after resection of tumor tissue, while the serum GP73 remained stable. These data indicated that the background of cirrhosis was related to the elevation of serum GP73 in HCC patients. In conclusion, serum GP73 is not a suitable diagnostic marker for HCC.

show abstract

“…Recently, an established hepatocellular carcinoma (HCC) biomarker, serum Golgi protein 73 (GP73), was reported to be correlated with disease severity in chronic hepatitis B (CHB) . The increased serum GP73 in HCC is argued to be attributed to the presence of cirrhosis rather than HCC .…”

Section: Introductionmentioning

confidence: 99%

Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection

Wang

Liu

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Transient elastography (TE) is accurate in staging fibrosis noninvasively. However, a reliable serum biomarker with comparable accuracy is also important, especially when TE is unreliable/unavailable. Therefore, we aimed to evaluate the diagnostic performance of serum Golgi protein 73 (GP73) for significant fibrosis in patients with chronic HBV infection. A total of 801 patients with chronic liver disease (CLD; 492 chronic HBV infection and 309 non-HBV liver disease) with liver biopsy performance were enrolled. Healthy controls (n = 180) and hepatocellular carcinoma (HCC) patients (n = 85) were included for comparisons. Liver biopsy was used as the reference method for fibrosis staging. Serum GP73 level was measured in duplicate in double-blind fashion. Serum GP73 was highest in HCC but also significantly higher in chronic hepatitis B than in healthy controls. The elevation of serum GP73 in non-HCC patients was significantly associated with the presence of significant fibrosis independently of ALT level, liver stiffness (LS) value, inflammation grade and other confounding factors. The diagnostic performance of serum GP73 was accurate in antiviral-naïve HBV patients (area under the receiver operating curve [AUROC], 0.76 95% CI: 0.72-0.81) but not in patients with ongoing antiviral treatment (AUROC, 0.60). The utility of serum GP73 was also confirmed in non-HBV CLD (AUROC, 0.80 95% CI: 0.75-0.85). Serum GP73 was comparable to LS (AUROC, 0.78 95% CI: 0.73-0.82) and significantly better than AST to platelet ratio index (APRI) (AUROC, 0.67 95% CI: 0.62-0.72) and FIB-4 (AUROC, 0.68 95% CI: 0.63-0.73). In conclusion, serum GP73 is an accurate serum marker for significant fibrosis in chronic HBV infection, with higher accuracy than APRI and FIB-4. Serum GP73 is potentially a complementary tool for TE when evaluating the necessity of antiviral treatment, particularly in patients without definite antiviral indication.

show abstract

Serum GP73, a Marker for Evaluating Progression in Patients with Chronic HBV Infections

Cited by 37 publications

References 29 publications

Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection

Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection

Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma

Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection

Contact Info

Product

Resources

About